Once you and your doctor have decided that immediate release Sandostatin® (octreotide acetate) Injection is well tolerated and effective for you, you can begin 28-day injections with Sandostatin® LAR Depot (octreotide acetate for injectable suspension).
After 3 months on Sandostatin® LAR Depot, your doctor will assess your progress to see if the dosage should be adjusted. Remember to always report any symptoms as accurately as possible, so your doctor will know the best dosage for you. Remember also that it is important to maintain a regular, 28-day schedule of visiting your healthcare professional.
- Find out about reimbursement for Sandostatin® LAR Depot
- Find out about the Nurse Home Injection Program for Sandostatin® LAR Depot
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
